OpenAI opens its life sciences model to US academic labs after a trusted-access review

OpenAI · Company post

Read the source (opens in a new tab)
What happened
OpenAI announced the Rosalind Academic Plan on October 15, 2026, giving eligible labs at US universities free Business Standard seats and access to GPT-Rosalind, its life sciences model, "subject to trusted-access approval."
Key points
  • Labs get up to 30 Business Standard seats at $0 per user per month for up to 12 months and GPT-Rosalind once approved; API access is not included at this time.
  • Through trusted access, approved researchers can "investigate sensitive scientific questions within safeguards designed for legitimate research," in areas that include antibodies and vaccines against emerging viral variants and host-pathogen interactions.
  • Before activation OpenAI verifies the institution and lab lead's identity, reviews the lead's background and authority, assesses the lab's research and intended use, and sets responsibilities for the lead and "a designated institutional safety contact."
  • "Safeguards continue after activation through monitoring and enforcement"; for registered high-sensitivity use cases OpenAI says its safety checks account for the approved research context, and it may follow up with researchers to confirm authorization.
Evidence
Company announcement describing the plan's terms and OpenAI's stated review and monitoring process. It shows the design, not how the review or monitoring performs. Universities with an existing Enterprise agreement apply through that route instead.
Uncertain
The page does not say what the trusted-access review rejects, what counts as a high-sensitivity use case, or how safety checks change for one.

See it in the latest record